# dehaze

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dehaze

- Industry: Healthcare IT
- Headquarters: Munich, Germany
- Website: www.dehaze.de
- Total disclosed funding: $3.7M
- Latest round: Seed (Apr 2, 2026)
- Investors on record: 5

## About

Based in Germany, dehaze GmbH specializes in artificial intelligence solutions aimed at enhancing healthcare through proactive risk management and improved patient outcomes.Founded in 2023 by Marius Klages, Jan Baumbach, and Julian Matschinske, dehaze GmbH operates from Munich, Germany, focusing on AI-driven healthcare solutions. The company has engaged in a single funding deal, raising EUR 3.2 million in Seed funding on April 2, 2026, from investors including YZR and DN Capital. The founder's background details are not specified, but the firm has a current valuation of EUR 12.982 mn.dehaze GmbH offers an innovative AI-powered healthcare solution aimed at transforming the current reactive healthcare model into a proactive one. Their core technology serves as an AI copilot designed to identify overlooked diagnoses, inappropriate treatments, and future health risks by analyzing diverse health data formats, including lab values, images, genomics, and handwritten notes. By mapping this data onto patient journeys and employing a doctor-in-the-loop process for cleansing and validating information, dehaze provides actionable insights that empower healthcare providers to deliver better preventative care. Target users of this technology include healthcare providers, payers, and patients across various markets, specifically focusing on private health networks in Europe and potentially expanding to other regions where chronic disease management is a challenge.dehaze GmbH generates revenue through partnerships with healthcare organizations and subscription-based models, offering their AI-driven services to hospitals, clinics, and insurance companies. These partnerships enable healthcare providers to access dehaze's platform, allowing them to utilize advanced AI algorithms for risk profiling and patient follow-ups. While specific pricing structures are not disclosed, the company offers a range of services that include proactive risk notifications and AI-assisted patient management. The revenue model emphasizes collaboration with healthcare entities, indicating a B2B approach that leverages dehaze's technology to enhance patient outcomes and reduce overall healthcare costs.In April 2026, dehaze GmbH raised EUR 3.2 million in Seed funding co-led by new investors YZR and DN Capital, with participation from Angel Invest Ventures, Zoho.vc, and better ventures. The company will utilize the funding to support international demand, grow its technical and commercial teams, and advance and scale its chronic disease detection platform. Future growth plans include the design and launch of new products tailored for broader applications, along with targeted expansions into additional European markets and potentially beyond, aligning with their strategy to address chronic disease management challenges more effectively.

## Funding rounds

- Seed, Apr 2, 2026, $3.7M — DN Capital, Angel Invest Ventures, YZR, better ventures, Zoho.vc

## Investors

- DN Capital (https://capitalatlas.ai/funds/dn-capital) — Seed
- Angel Invest Ventures (https://capitalatlas.ai/funds/angel-invest-ventures) — Seed
- YZR (https://capitalatlas.ai/funds/yzr) — Seed
- better ventures — Seed
- Zoho.vc (https://capitalatlas.ai/funds/zoho-vc) — Seed